Literature DB >> 14605680

Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines.

Mauricio M Rodrigues1, Silvia B Boscardin, José R Vasconcelos, Meire I Hiyane, Gerson Salay, Irene S Soares.   

Abstract

Obligatory intracellular parasites such as Plasmodium sp, Trypanosoma cruzi, Toxoplasma gondii and Leishmania sp are responsible for the infection of hundreds of millions of individuals every year. These parasites can deliver antigens to the host cell cytoplasm that are presented through MHC class I molecules to protective CD8 T cells. The in vivo priming conditions of specific CD8 T cells during natural infection are largely unknown and remain as an area that has been poorly explored. The antiparasitic mechanisms mediated by CD8 T cells include both interferon-gamma-dependent and -independent pathways. The fact that CD8 T cells are potent inhibitors of parasitic development prompted many investigators to explore whether induction of these T cells can be a feasible strategy for the development of effective subunit vaccines against these parasitic diseases. Studies performed on experimental models supported the hypothesis that CD8 T cells induced by recombinant viral vectors or DNA vaccines could serve as the basis for human vaccination. Regimens of immunization consisting of two different vectors (heterologous prime-boost) are much more efficient in terms of expansion of protective CD8 T lymphocytes than immunization with a single vector. The results obtained using experimental models have led to clinical vaccination trials that are currently underway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605680     DOI: 10.1590/s0001-37652003000400005

Source DB:  PubMed          Journal:  An Acad Bras Cienc        ISSN: 0001-3765            Impact factor:   1.753


  19 in total

1.  Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites.

Authors:  Farokh Dotiwala; Sachin Mulik; Rafael B Polidoro; James A Ansara; Barbara A Burleigh; Michael Walch; Ricardo T Gazzinelli; Judy Lieberman
Journal:  Nat Med       Date:  2016-01-11       Impact factor: 53.440

2.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice.

Authors:  Fanny Tzelepis; Bruna C G de Alencar; Marcus L O Penido; Ricardo T Gazzinelli; Pedro M Persechini; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

4.  Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Authors:  Matthew H Collins; Julie M Craft; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

5.  Chlamydia trachomatis-infected epithelial cells and fibroblasts retain the ability to express surface-presented major histocompatibility complex class I molecules.

Authors:  Danny Kägebein; Melanie Gutjahr; Christina Große; Annette B Vogel; Jürgen Rödel; Michael R Knittler
Journal:  Infect Immun       Date:  2013-12-16       Impact factor: 3.441

6.  Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.

Authors:  Raquel T Nogueira; Alanderson R Nogueira; Mirian C S Pereira; Maurício M Rodrigues; Ricardo Galler; Myrna C Bonaldo
Journal:  Virol J       Date:  2011-03-18       Impact factor: 4.099

7.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

8.  Vaccination against murine toxoplasmosis using recombinant Toxoplasma gondii SAG3 antigen alone or in combination with Quil A.

Authors:  Young-Ha Lee; Dae-Whan Shin; Jae-Ho Lee; Ho-Woo Nam; Myoung-Hee Ahn
Journal:  Yonsei Med J       Date:  2007-06-30       Impact factor: 2.759

9.  Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.

Authors:  Rafael Polidoro Alves Barbosa; Bruno Galvão Filho; Luara Isabela Dos Santos; Policarpo Ademar Sales Junior; Pedro Elias Marques; Rafaela Vaz Sousa Pereira; Denise Carmona Cara; Oscar Bruña-Romero; Maurício Martins Rodrigues; Ricardo Tostes Gazzinelli; Alexandre Vieira Machado
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

10.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.